Log in to search using one of your social media accounts:

 

'Black witch' claims she can cure people of CANCER
A 46-year-old called Savannah, or Black Witch S, from Louisiana, claims she's 'healed' a 23-year-old Los Angeles police officer with leukaemia by arranging a 'pact with Lucifer'. (Source: the Mail online | Health)
Source: the Mail online | Health - September 22, 2017 Category: Consumer Health News Source Type: news

Family: Leukemia patient's stem cell donor repeatedly denied visa
Doctors say Helen Huynh will die without a transplant and while her sister is a perfect match, she's in Vietnam and can't get a temporary visa (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 22, 2017 Category: Consumer Health News Source Type: news

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Nigeria: Leukemia Patients Celebrate 10th World CML Day
[This Day] As patients of Chronic Myeloid Leukemia (CML) worldwide celebrate the 10th World CML Day today to raise awareness on a rare haematological disease that represents 15 to 20 per cent of all leukemia in adults and the needs of patients, a non-governmental organisation, Together Maxcare Foundation Nigeria, is pushing for more sensitivity to the plight of patients who have this rare type of leukemia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 22, 2017 Category: African Health Source Type: news

Boy meets bone marrow donor who saved his life
The second-grader who beat leukemia met his bone marrow donor live on "GMA." (Source: ABC News: Health)
Source: ABC News: Health - September 21, 2017 Category: Consumer Health News Tags: Health Source Type: news

HLA-mismatched Microtransplant Benefits Older AML Patients HLA-mismatched Microtransplant Benefits Older AML Patients
Most older patients with newly diagnosed acute myeloid leukemia (AML) achieve complete remission and good overall survival after HLA-mismatched microtransplant, according to results from 12 centers in China, the United States, and Spain.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

WATCH: Boy, 8, meets the bone marrow donor who saved his life, live on 'GMA'
For the first time, an 8-year-old leukemia survivor meets the woman who donated bone marrow to save his life. (Source: ABC News: Health)
Source: ABC News: Health - September 20, 2017 Category: Consumer Health News Tags: GMA Source Type: news

How to manage family life when your child has cancer
Valerie, with husband Doron, son Evan and daughter Ruby When our daughter, Ruby, was diagnosed with acute lymphoblastic leukemia (ALL) at one and a half years old, my husband and I were immediately transformed from working parents with two young children, to parental caregivers for a child with cancer. Between hospital stays, medications and appointments, there was so much to keep track of. It can be overwhelming at times, but there are ways to manage life after your child is diagnosed with cancer. Settle into to this new normal. It can be easy to stay in crisis mode when something like a cancer diagnosis interrupts y...
Source: Thrive, Children's Hospital Boston - September 20, 2017 Category: Pediatrics Authors: Valerie Graf Tags: Diseases & Conditions Parenting Cancer Dana-Farber/Boston Children's Cancer and Blood Disorders Center Source Type: news

Boy, 8, meets the bone marrow donor who saved his life
The second-grader who beat leukemia met his bone marrow donor live on "GMA." (Source: ABC News: Health)
Source: ABC News: Health - September 20, 2017 Category: Consumer Health News Tags: Health Source Type: news

WATCH: Boy, 8, meets the bone marrow donor who saved his life live on 'GMA'
An 8-year-old leukemia survivor meets the woman who donated her bone marrow to save his life for the first time. (Source: ABC News: Health)
Source: ABC News: Health - September 20, 2017 Category: Consumer Health News Tags: GMA Source Type: news

Novartis's Rydapt wins EU approval for AML, other diseases
ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukaemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukaemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukaemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10 percent of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news

Mesothelioma Clinical Trials Involve Gene Therapy
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
Source: Asbestos and Mesothelioma News - September 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news

Ludwig scientists discover complex axis of immune suppression exploited by cancers
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has uncovered a new mechanism by which cancer cells evade destruction by the immune system. The paper, led by Camilla Jandus of the Lausanne Branch of the Ludwig Institute for Cancer Research, describes how immune cells known as group 2 innate lymphoid cells (ILC2s) are recruited by leukemic cells to suppress an essential anticancer immune response. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 19, 2017 Category: International Medicine & Public Health Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Media News)
Source: Roche Media News - September 18, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: MDS symptoms: What are the signs of pre-leukemia?
MDS, or myelodysplastic syndrome, refers to a group of blood cancers. In this article, learn about the symptoms and complications of this disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 15, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

GATA1 as a Marker for Erythroid and Megakaryocytic Lineages GATA1 as a Marker for Erythroid and Megakaryocytic Lineages
This study investigated the use of GATA binding factor 1 as a marker for neoplastic cells of pure erythroleukemia and acute megakaryoblastic leukemia.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 14, 2017 Category: American Health Source Type: news

Adult Acute Lymphoblastic Leukemia (ALL)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 14, 2017 Category: General Medicine Source Type: news

MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news

Antibiotic identified that reduces infection risk in young leukemia patients
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital investigators report preventive antibiotic therapy, particularly with levofloxacin, reduced the odds of infections in at-risk pediatric leukemia patients early in cancer treatment. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2017 Category: Infectious Diseases Source Type: news

WATCH: Irma prompts hospital to hold birthday for 3-year-old with leukemia
Willow Stine was diagnosed with cancer just two days before her third birthday. (Source: ABC News: Health)
Source: ABC News: Health - September 13, 2017 Category: Consumer Health News Tags: Health Source Type: news

Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment
Canadian drug discovery and development company Pascal Biosciences has executed an exclusive, worldwide licence option agreement with STC.UNM (STC) to purchase a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukaemia (BCP- … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia
Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Inhibitors support immune therapy for leukemia
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from the German Cancer Consortium (DKTK) and the Munich University Hospital and T ü bingen University Hospital have shown that, in conjunction with certain inhibitors, this form of therapy could be successful in even more patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Irma threatens birthday for 3-year old with leukemia, until nurses step in
When Hurricane Irma threatened to ruin Willow Stine's third birthday party, hospital staff in St. Petersburg, Florida, came to the rescue. (Source: CNN.com - Health)
Source: CNN.com - Health - September 11, 2017 Category: Consumer Health News Source Type: news

Future Cancer Treatment in New Cancer Gene Therapy
1 day ago ... ... including lymphoma and other forms of leukemia," Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, tells AARP. (Source: AARP.org News)
Source: AARP.org News - September 10, 2017 Category: American Health Source Type: news

Residents Cough, Rub Eyes in Harvey Pollution Spike
GALENA PARK, Texas (AP) — Cindy Sanchez began to feel ill while barbecuing just before Harvey's torrents started pelting this city just east of Houston, along a corridor with the nation's highest concentration of petrochemical plants. "I started getting really, really bad headaches," said Sanchez, a 32-year-old housewife. "I never get headaches." "My husband's eyes were burning," she said. "He actually had a napkin that was wet over his eyes." The sewage-like stench chased the couple indoors and Sanchez, sick to her stomach, lay down. People complained of headaches, nausea, itc...
Source: JEMS: Journal of Emergency Medical Services News - September 8, 2017 Category: Emergency Medicine Authors: Frank Bajak and Michelle Minkoff, Associated Press Tags: Major Incidents News Source Type: news

Verastem improves progression-free survival in Phase III trial for CLL and SLL
US-based biopharmaceutical firm Verastem has reported positive top-line results from the Phase III DUO clinical trial of duvelisib to treat relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Researchers point way to improved stem cell transplantation therapies
(Rockefeller University Press) Researchers in Germany have demonstrated that hematopoietic stem cell (HSC) transplants can be improved by treatments that temporarily prevent the stem cells from dying. The approach, which is described in a paper to be published Sept. 7 in The Journal of Experimental Medicine, could allow those in need of such transplants, including leukemia and lymphoma patients, to be treated with fewer donor stem cells while limiting potential adverse side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2017 Category: Cancer & Oncology Source Type: news

Immune Status Tied to Outcomes in Third - Gen CAR T - Cell Therapy
In leukemia/lymphoma, after treatment CD19 - targeting chimeric antigen receptor T - cell therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 6, 2017 Category: Cancer & Oncology Tags: Oncology, Pathology, Conference News, Source Type: news

Bone marrow models to study blood and musculoskeletal disorders
(Karlsruher Institut f ü r Technologie (KIT)) For her research on development of hematological and musculoskeletal disorders, Dr. Cornelia Lee-Thedieck, scientist at Karlsruhe Institute of Technology, is awarded an ERC Starting Grant: The European Research Council decided to fund her project 'bloodANDbone' with€1.5 million for five years. Lee-Thedieck develops models of the human bone marrow to study the regeneration of blood and bone by stem cells and how this regeneration is disturbed in diseases like leukemia or bone metastases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 6, 2017 Category: International Medicine & Public Health Source Type: news

TC BioPharm Announces CAR-T Licensing Deal With UCL Business
UCL academics will assist TCB with development of treatment for leukemia. Clinical programme will see first patients treated in 2018.(PRWeb September 06, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14660669.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 6, 2017 Category: Pharmaceuticals Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 5, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. How medical device risk management is connected with design controls Medical device design controls play an important role when it comes to risk management, but the relationship isn’t always immediately clear. Intended us...
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

FDA approves Mylotarg to treat acute myeloid leukemia
The U.S. Food and Drug Administration approved Mylotarg, or gemtuzumab, for the treatment of adults with newly diagnosed acute myloid leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 5, 2017 Category: Consumer Health News Source Type: news

Novartis CEO departs, leaving corner office to Harvard doc
Novartis‘ (NYSE:NVS) chief executive Joseph Jimenez is slated to leave his post next February, the drugmaker reported over the weekend. The CEO’s surprise departure leaves the corner office to Dr. Vasant Narasimhan, who currently serves as the company’s CMO and global head of drug development. The move comes just days after Novartis won FDA approval for its breakthrough CAR-T leukemia therapy – the first of its kind to be cleared in the U.S. Get the full story at our sister site, Drug Delivery Business News. The post Novartis CEO departs, leaving corner office to Harvard doc appeared first on M...
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Pharmaceuticals Wall Street Beat GlaxoSmithKline plc Novartis Roche Source Type: news

Pfizer ’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment
The US Food and Drug Administration (FDA) has granted approval to Pfizer ’s antibody-drug conjugate (ADC) Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with acute myeloid leukaemia (AML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 3, 2017 Category: Pharmaceuticals Source Type: news

Morning Rounds: Flooding health concerns, Harvey's emotional toll
Dr. David Agus joins "CBS This Morning: Saturday" from Los Angeles to discuss some of the health concerns for survivors of Hurricane Harvey, a potential breakthrough in the way we fight cardiovascular disease and a new FDA-approved gene therapy in the U.S. that treats children and young adults with leukemia. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 2, 2017 Category: Consumer Health News Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug
At lower dose, Mylotarg extended survival against a certain type of blood cancer (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 2, 2017 Category: Cancer & Oncology Source Type: news

FDA OKs Return of Once - Withdrawn Leukemia Drug
At lower dose, Mylotarg extended survival against a certain type of blood cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 2, 2017 Category: Cancer & Oncology Tags: Nursing, Oncology, Pharmacy, News, Source Type: news

FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia
September 1, 2017 -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug
At lower dose, Mylotarg extended survival against a certain type of blood cancer Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 1, 2017 Category: Consumer Health News Source Type: news

Mylotarg Back on Market with New FDA Approval
(MedPage Today) -- Smaller doses OK'd for certain acute myeloid leukemia indications (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 1, 2017 Category: American Health Source Type: news

Mylotarg Approved for AML: Drug Returns to Market Mylotarg Approved for AML: Drug Returns to Market
After being voluntarily withdrawn 7 years ago, gemtuzumab ozogamicin (Mylotarg) is now returning to the market for the treatment of acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug, Mylotarg
FRIDAY, Sept. 1, 2017 -- The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia -- CD33-positive AML. An earlier version of the drug had been withdrawn... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 1, 2017 Category: General Medicine Source Type: news

FDA approves Pfizer's leukemia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML). (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
SILVER SPRING, Md., Sept. 1, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors expres... Biopharmaceuticals, Oncology, FDA Pfizer, Mylotarg, gemtuzumab ozogamicin, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2017 Category: Pharmaceuticals Source Type: news